临床肝胆病杂志2025，Vol.41Issue(10)：2136-2140,5.DOI:10.12449/JCH251026
代谢相关脂肪性肝病与胰腺癌风险关联的流行病学及机制研究进展
Research advances in the epidemiology and mechanism of the association between metabolic dysfunction-associated fatty liver disease and pancreatic cancer
摘要
Abstract
Metabolic dysfunction-associated fatty liver disease(MAFLD)has a relatively high prevalence rate around the world and is closely associated with the development of various extrahepatic malignancies,among which pancreatic cancer exhibits the highest mortality rate.However,the underlying mechanism between MAFLD and pancreatic cancer remains unclear.This article systematically introduces the latest epidemiological evidence of the association between MAFLD and pancreatic cancer,reviews the research advances in pathogenesis,and evaluates the impact of MAFLD severity and high-risk factors(such as nonalcoholic fatty pancreatic disease and intraductal papillary mucinous neoplasm)on the risk of pancreatic cancer.This article points out that insulin resistance,adipokines,and gut dysbiosis may be the key mechanisms of MAFLD promoting the onset of pancreatic cancer,and it also highlights the presence of heterogeneity in current studies.Large-scale prospective cohort studies are needed in the future to further validate the causal relationship and explore more effective strategies for risk stratification.关键词
代谢相关脂肪性肝病/胰腺肿瘤/危险因素/病理过程Key words
Metabolic Dysfunction-Associated Fatty Liver Disease/Pancreatic Neoplasms/Risk Factors/Pathologic Processes引用本文复制引用
张锋,张一帆,刘玉兰..代谢相关脂肪性肝病与胰腺癌风险关联的流行病学及机制研究进展[J].临床肝胆病杂志,2025,41(10):2136-2140,5.基金项目
北京市自然科学基金项目(7242156) （7242156）
首都卫生发展科研专项重点攻关项目(CFH2024-1-4081) （CFH2024-1-4081）
国家自然科学基金面上项目(82100579) （82100579）
北京大学人民医院科研发展基金项目(RDX2022-07) Beijing Natural Science Foundation(7242156) （RDX2022-07）
Key Research Project of Capital Health Development Scientific Research Special Program(CFH2024-1-4081) （CFH2024-1-4081）
General Project of National Natural Science Foundation of China(82100579) （82100579）
Peking University People's Hospital Scientific Research Development Funds(RDX2022-07) （RDX2022-07）
